ATLANTA, GA – – (Globe Newswire – September 11, 2023) – – Holzer & Holzer, LLC is investigating whether Outlook Therapeutics, Inc. (“Outlook Therapeutics” or “the Company”) (NASDAQ: OTLK) complied with federal securities laws. On August 30, 2023, Outlook Therapeutics announced the FDA “issued a CRL to the Company’s BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, the Agency concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.” Following this news, the price of the Company’s stock dropped.
If you purchased Outlook Therapeutics stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at firstname.lastname@example.org or Joshua Karr, Esq. at email@example.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/outlook-therapeutics/ to discuss your legal rights.